News

Bristol Myers Squibb (NYSE:BMY) reported positive Phase III SUCCESSOR-2 trial results in multiple myeloma at a major medical conference. The company highlighted early clinical success for a new CAR T-cell therapy targeting blood cancers. Bristol Myers Squibb appointed a new General Manager to lead its operations across the Gulf region. Bristol Myers Squibb is a large biopharmaceutical company with a long-standing focus on oncology and hematology treatments. The fresh readout from the...

Illumina (NasdaqGS:ILMN) has launched new oncology research tools, including the fully automated fireflyGO platform for targeted cancer workflows. The company has expanded its research panels for solid and blood cancers, aiming to support more precise tumor profiling. Illumina introduced its first distributed whole genome MRD research kit, validated with partners such as Mayo Clinic and highlighted with Bristol Myers Squibb at ASCO. For investors tracking Illumina, this update adds product...